Base editing. Criticism of its use in embryos to create designer babies By Bioethics Observatory

Base editing. Criticism of its use in embryos to create designer babies By Bioethics Observatory Published On: July 10th, 2026 Categories: Bioethics, BIOETHICS NEWS, Genetics and Genomics, SPECIAL REPORTS Base editing, a refined form of the widely-known CRISPR-Cas9 technique, allows precise chemical changes to be made in a single DNA letter without cutting the DNA’s double helix. Although this technical innovation broadens the horizon for correcting certain mutations, its clinical application in human embryos for reproductive purposes is associated with serious safety risks, technical inefficiencies, and profound bioethical dilemmas. In this article, we analyze why germline modification—associated with risks such as mosaicism and unpredictable harmful effects—and the false transhumanist promise of “human enhancement” open the door to eugenic practices that directly violate human dignity. In light of the alarming trend toward biotechnological commodification, driven by the dangerous illusion of the “perfect baby” through embryo selection and disposal, there is an urgent need to call for scientific realism, prudence, and ethical reflection to safeguard developing human lives. https://bioethicsobservatory.org/2026/07/base-editing-criticism-of-its-use-in-embryos-to-create-designer-babies/48927/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Scientists succeed in producing immune cells capable of attacking tumors By Bioethics Observatory

Scientists succeed in producing immune cells capable of attacking tumors By Bioethics Observatory Published On: September 8th, 2026 Categories: Bioethics, BIOETHICS NEWS, Gene Therapy, SPECIAL REPORTS A group of scientists from the University of Southern California has developed a method to continuously produce progenitor cells capable of generating macrophages, a type of cell essential for the functioning of the immune system. In a study published in the journal Cell, researchers describe a new technique for obtaining a renewable and expandable supply of granulocyte and monocyte progenitor cells (GMP), precursors of different types of immune cells, including macrophages. These immune cells contribute to the body’s resp... https://bioethicsobservatory.org/2026/09/scientists-succeed-in-producing-immune-cells-capable-of-attacking-tumors/48994/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

The Netherlands records its first child euthanasia case By Bioethics Observatory

The Netherlands records its first child euthanasia case By Bioethics Observatory Published On: September 7th, 2026 Categories: Bioethics, BIOETHICS NEWS, Euthanasia, SPECIAL REPORTS The Netherlands has recorded its first case of euthanasia performed on a child between the ages of one and twelve since expanding its legislation in 2024. The case, in which neither the child’s age nor illness has been revealed, reopens the debate about the consequences of extending euthanasia to those who cannot give informed consent and about the responsibility of parents, doctors, judges, and legislators regarding the lives of the most vulnerable. The Netherlands has recorded its first case of euthanasia performed on a child between the ages of one and twelve since the law allowing it for minors with incurable illnesses that cause unbearable suffering with no possibility of improvement came into effect in 2024. The procedure requires parental consent and an assessment by at least one independent physician. https://bioethicsobservatory.org/2026/09/the-netherlands-records-its-first-child-euthanasia-case/48980/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

From guide RNA to guide DNA: a new paradigm in CRISPR technology By Bioethics Observatory

From guide RNA to guide DNA: a new paradigm in CRISPR technology By Bioethics Observatory Published On: June 23rd, 2026 Categories: Bioethics, BIOETHICS NEWS, Genetics and Genomics, SPECIAL REPORTS CRISPR technology, which has traditionally relied on guide RNA molecules to locate specific genetic sequences, may be entering a new era with the development of DNA-guided systems. This paradigm shift promises more stable, precise, and versatile gene editing tools, expanding the possibilities of intervention on genetic material and opening new avenues in diagnostics, biomedical research, and advanced therapies. Regardless of the level of cellular organization, all living beings share a set of fundamental organic molecules that are organized into a wide variety of structural and functional compounds. These molecules form part of both internal and external cellular structures, and interactively perform multiple biological functions. Among these compounds, the most important molecules as regards biological information and the functioning of life are nucleic acids—DNA and RNA—and proteins. https://bioethicsobservatory.org/2026/06/from-guide-rna-to-guide-dna-a-new-paradigm-in-crispr-technology/48904/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Relief from suffering: An inalienable right from the beginning of life By Bioethics Observatory

Relief from suffering: An inalienable right from the beginning of life By Bioethics Observatory Published On: July 1st, 2026 Categories: Bioethics, BIOETHICS NEWS, Palliative Care, SPECIAL REPORTS Palliative care, which should be used when it is not possible to cure the patient, but it is possible to relieve their suffering and accompany them in the process of their illness in a multidisciplinary way, should not only be geared towards adulthood but to any stage of human life. Addressing pain and suffering in the earliest stages of human life represents one of the great clinical and ethical challenges of our time. Traditionally, healthcare has tended to extrapolate adult treatment models to the pediatric population, a fundamental error that modern bioethics and pediatric palliative care specialists are striving to correct. https://bioethicsobservatory.org/2026/07/relief-from-suffering-an-inalienable-right-from-the-beginning-of-life/48914/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Diabetes in a warming world The Lancet Diabetes & Endocrinology ++... ++

Diabetes in a warming world The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00217-2/fulltext?dgcid=raven_jbs_etoc_email Oct 2026 Volume 14Number 10p793-866 https://www.thelancet.com/journals/landia/issue/vol14no10/PIIS2213-8587(26)X2008-3 Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial Prof Daisuke Yabe, MDa ∙ Toshihiko Shiraiwa, MDb ∙ Hiroyuki Ugai, MSc ∙ Dr Masakazu Takeuchi, PhDc Send email to takeuchi_masakazu@lilly.com ∙ Prof Ryo Suzuki, MD https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00138-5/abstract?dgcid=raven_jbs_etoc_feature_landia Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial Prof Lixin Guo, MDa Send email to guolixin3234@bjhmoh.cn ∙ Xiaolei Bao, PhDb ∙ Prof Kuo-Chin Huang, MD PhDd ∙ Kristoffer Jensen Kolnes, MD PhDe ∙ Christian Laugesen, MD PhDe ∙ Yibing Lu, MDf ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00133-6/abstract?dgcid=raven_jbs_etoc_feature_landia

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD

https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_stan_mscpedu_260908-OUS-HONC-enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46-cta&uac=148436CN

How to Help Manage Depression After GLP-1 Weight Regain Erica Lamberg

https://www.medscape.com/viewarticle/how-help-manage-depression-after-glp-1-weight-regain-2026a1000xan?ecd=WNL_trdalrt_pos1_ous_260909_etid8675509&uac=148436CN&impID=8675509 With more patients using GLP-1 weight-loss medications, physicians are increasingly seeing patients who discontinued therapy because of cost, limited pharmacy availability, intolerable adverse effects, or loss of insurance coverage.

Tenosynovial Giant Cell Tumor in Focus: Quickfire Insights From Multidisciplinary Experts Authors: Hans Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD

https://www.medscape.org/viewarticle/tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py?page=1&src=mkmcmr_driv_stan_mscpedu_260909-OUS-HONC-tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py-cta&uac=148436CN

Read our latest conference content ++++ +++ Explore our content presented at ERS Congress 2026

ARTICLES Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial Free with registration https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01655-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz-9XsYRBb0T_0ICIOJjh-RznGP81TYNtYrKDI-rOTxfUOTuBNxGkeo8A8BrBcRvMYoneC8-tfndUdHh3nirISwyBWbFDnQ&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Cryobiopsy versus conventional bronchoscopic sampling for peripheral pulmonary lesions (Cryo-RCT): an open-label, parallel-group, randomised trial Free with registration until Sept 17th, 2026 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00191-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz--tnfkkQFT_LC8QXD5COgm4JZ4eyh5o_QwC4xzPF1YJ1Mox2vpZyvnw0CDv6lSP_J5qGaGdsqAiHO47qmxLB1pfdqIBjA&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study Free with registration until Sept 17th, 2026 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00257-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz-_EjlieFJhIiDCnWzkwgYaYCpQsb2hei-EdTCVk9vbiYo0tQAWjZTc-RbN1apsdxFWJAZ_0I4LxQy07nrr3PKrueSrJHw&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 Open Access https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00168-4/fulltext?dgcid=hubspot_email_conferencealerts_ers26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_cye-e0ydnBpRixMtqXhbWnsrCPzWGx5sUNH9mNc7fCEr6-zNpZ_NJJoqQg3Dwhv062iOPy9t5aiidiccyGDHA7bZfUw&_hsmi=437945858&utm_content=437945858&utm_source=hs_email SERIES The changing therapeutic landscape of small-cell lung cancer Free with registration https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01244-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz-9l4htBAutdFpCfux9Fg6xQo2i6sJKPWy1MNZ3v3dLOSqgvIaSbOSn55JgT_hkrSQh5ySIcT7AB35EanmsY9bYmYK83Tg&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies Free with registration https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00253-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz--AARarKR9JMTBR-I-8elbu2fwvSF-V3S3RhrcdWToSgwYYsJbhhKLM4PRSF68QSaRZ5-CQc_o-oz7Sb4UtiDsXBIpHVA&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00221-3/fulltext?dgcid=hubspot_email_conferencealerts_ers26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--aP8eppIpfR-zEzT9CjEDUUETVDdgW0aL3NPiw8jiAzUybGoqIiixDj2bSPGwdmJSdi-cLJLjQsiHvn_R7ziZ78Ag4lg&_hsmi=437945858&utm_content=437945858&utm_source=hs_email

Funding news for global health researchers: September 7, 2026

Focus on HIV An estimated 40.9 million people globally are living with human immunodeficiency virus (HIV), first identified in the early 1980s. Remarkable scientific progress over four decades has led to the development of effective antiretroviral therapy (ART). In response to effective treatments and strategies, health care systems have begun to change; people living with HIV, once considered “too complex” for primary care, are returning to that setting. https://www.fic.nih.gov/?utm_source=funding-news&utm_medium=email&utm_campaign=funding-news

Beyond medical fit: redefining patient readiness in clinical trials 7 September 2026

https://rarerevolutionmagazine.com/beyond-medical-fit-redefining-patient-readiness-in-clinical-trials/ Clinical trials can offer a lifeline for rare disease patients, but the journey often demands more than just medical eligibility. trialport’s readifit™ tool looks to address this by empowering individuals to look beyond ‘medical fit’, evaluating their personal readiness and support networks to ensure they can stay the course, reducing dropouts through truly informed choices Written by Emma Bishop Interview with Dr Angelika Grechnaya, Ethan Graff-Radford, Lathe Ward and Charles Myrick, trialport With just 5% of rare diseases having an approved medicinal product1 a clinical trial can offer hope where there is none. However, there can be an assumption that this offer of hope means people will willingly take part and are able to do so. The impact of a clinical trial can bring unforeseen burdens and understanding these before consent is given is key. Dr Angelika Grechnaya is a counselling psychologist and has worked with trialport for the past eight months. She explains that medical fit is only the first gate to understanding whether someone is ready for a trial. The second stage is looking at whether someone can sustain participation. The decision goes from “Can I start?” to “Can I stay?” As Angelika explains, “To stay in a clinical trial is not one decision. You need to say multiple yeses. ‘Do I have enough time, enough money, enough support, is the trial aligned with what feels right for me, am I ok if the outcome is not what I expect?’” There are multiple factors that contribute to dropout rates:

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small

Two independent teams identify a key molecule that may help overcome immunotherapy resistance Researchers at Erasmus MC and Apeximmune independently identified PLA2G2D as a potential new target for restoring antitumor T cell responses. Written byBree Foster, PhD

Two independent teams identify a key molecule that may help overcome immunotherapy resistance Researchers at Erasmus MC and Apeximmune independently identified PLA2G2D as a potential new target for restoring antitumor T cell responses. Written byBree Foster, PhD https://www.drugdiscoverynews.com/two-independent-teams-identify-a-key-molecule-that-may-help-overcome-immunotherapy-resistance-17508 Two independent research teams have discovered the same previously overlooked immune checkpoint that may help explain why some cancers resist immunotherapy. In a study published today in Nature, researchers at Erasmus University Medical Center (Erasmus MC) identified phospholipase A2 group IID (PLA2G2D) in the tumor-draining lymph nodes (TDLNs) of patients with melanoma. The team found that the molecule acts as an immune checkpoint, essentially putting the brakes on the proliferation of tumor-reactive T cells before they reach the tumor.

Elevating CLL Care: Integrating Evidence, Guidelines, and the Patient Perspective Authors: Jennifer A. Woyach, MD; Stephan Stilgenbauer, MD; Lorna Warwick

https://www.medscape.org/viewarticle/elevating-cll-care-integrating-evidence-guidelines-and-2026a1000nxr?page=1&src=mkmcmr_driv_32025_mscpedu_436318.06_ace_launch&uac=148436CN

AI Streamlines Radiotherapy in Low-Resource Settings David Kerr, MD, DSc

https://www.medscape.com/viewarticle/ai-streamlines-radiotherapy-low-resource-settings-2026a1000trt?src=

Oncology Cases & Quizzes

https://www.medscape.com/index/list_12039_0 Fast Five Quiz: Relapsed and Refractory TNBC How much do you know about the treatment and management for relapsed and refractory triple-negative breast cancer? Test your knowledge with this quick quiz. Medscape Reference, September 08, 2026

RET Fusion Linked to Occult Lymph Node Metastasis in PTC Nancy A. Melville

https://www.medscape.com/viewarticle/ret-fusion-linked-occult-lymph-node-metastasis-ptc-2026a1000xer?src= RET fusion positivity was identified as an independent risk factor in occult lymph node metastasis in clinically lymph node negative (cN0) papillary thyroid cancer (PTC). In addition, BRAF mutation, a known risk factor for PTC, was also independently associated with occult lymph node metastasis. These molecular risk factors, along with other clinical and ultrasonographic factors, showed predictive accuracy in a new machine learning model for the prediction of occult lymph node metastasis in cN0 PTC. The authors caution, however, that further validation of the model in larger studies is needed.

Allo-HSCT Shows Long-Term Benefit in Hepatosplenic Lymphoma Edited by Gargi Mukherjee

https://www.medscape.com/viewarticle/allo-hsct-shows-long-term-benefit-hepatosplenic-lymphoma-2026a1000xdx?src= At 3 years, more than half of patients with hepatosplenic T-cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation (HSCT) were alive, according to a retrospective study. Lactate dehydrogenase at or below the upper limit of normal at diagnosis and complete remission before transplantation were both associated with significantly better survival outcomes. In patients receiving autologous transplantation, relapse occurred in 50% by 3 years, despite the majority being in complete remission at...

Bowel Cancer Under 50: Rethinking Screening and Diagnosis Sophie Cousins

https://www.medscape.com/viewarticle/bowel-cancer-under-50-rethinking-screening-and-diagnosis-2026a1000xfl?src= If there is one thing that Australians aged 45 years or older should do, it is to collect a fecal sample, according to Eleonora Feletto, PhD, associate professor of medicine and health at the University of Sydney.

A New PARADIGM? Azacitidine-Venetoclax Tops Induction Chemo in AML M. Alexander Otto, PA, MMSc

https://www.medscape.com/viewarticle/new-paradigm-azacitidine-venetoclax-tops-induction-chemo-aml-2026a1000xgj?src= The combination of azacitidine and venetoclax more than doubled event-free survival compared with standard induction chemotherapy among fit patients with previously untreated acute myeloid leukemia (AML), according to a phase 2 trial. Patients in the trial, dubbed PARADIGM, had high-risk disease and were eligible for chemotherapy induction. The half treated with azacitidine-venetoclax instead had longer event-free survival, at a median of 14.5 months vs 6.2 months with chemotherapy.

Do Pilots, Flight Crew Have Higher Cancer Mortality Risk? Megan Brooks September 08, 2026

https://www.medscape.com/viewarticle/do-pilots-flight-crew-have-higher-cancer-mortality-risk-2026a1000x9a US pilots and flight attendants had higher odds of dying from cancers potentially related to radiation exposure than workers in other occupations, according to a large analysis of US death certificate data. The researchers said their findings are consistent with prior epidemiologic studies linking aircrew work to higher cancer incidence, with the current study building on that research by examining cancer mortality among aircrew and about 500 other occupations.

Global Insights on Bispecific Antibodies in Non-Hodgkin Lymphoma Authors: Emmanuel Bachy, MD, PhD; Max S. Topp, MD; Gloria Iacoboni, MD, PhD

https://www.medscape.org/viewarticle/global-insights-bispecific-antibodies-non-hodgkin-lymphoma-2026a1000tyj?page=1

Navigating Advanced NSCLC: A Clinical Case Challenge Authors: Charlotte Warren; Amy Furedy, RN, OCN; Tristin Abair, PhD

https://www.medscape.org/viewarticle/navigating-advanced-nsclc-clinical-case-challenge-2026a1000tmr?page=1

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&src=mkmcmr_driv_stan_mscpedu_260909-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta&uac=148436CN

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative

RAS-Targeted Strategies in Pancreatic Cancer: Progress and Future Directions Authors: Brian M. Wolpin, MD, MPH; Eileen M. O’Reilly, MD, FASCO; Zev A. Wainberg, MD

https://www.medscape.org/viewarticle/ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260907-OUS-HONC-ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c-cta

The Reality of Care for HER2-Mutated Advanced NSCLC: Closing Community Gaps Authors: Charu Aggarwal, MD, MPH; Balazs Halmos, MD, MS; Soo-Ryum (Stewart) Yang, MD

https://www.medscape.org/viewarticle/reality-care-her2-mutated-advanced-nsclc-closing-community-2026a1000mfr?page=1&src=mkmcmr_driv_stan_mscpedu_260907-OUS-HONC-reality-care-her2-mutated-advanced-nsclc-closing-community-2026a1000mfr-cta&uac=148436CN

Now Enrolling: GALILEO-3 Trial Evaluating FLT201 for Adults With Gaucher Disease Type 1 by Madaline Spencer| Published on: Aug 10, 2026

Now Enrolling: GALILEO-3 Trial Evaluating FLT201 for Adults With Gaucher Disease Type 1 by Madaline Spencer| Published on: Aug 10, 2026 Priya Kishnani, MD, Professor and Chief of the Division of Medical Genetics at Duke University, discusses the GALILEO-3 clinical trial of FLT201 in adults with Gaucher disease type 1 (GD1). https://checkrare.com/now-enrolling-galileo-3-trial-evaluating-flt201-for-adults-with-gaucher-disease-type-1/

Data on Maribavir in Post-Transplant Cytomegalovirus by Madaline Spencer| Published on: Sep 8, 2026

Data on Maribavir in Post-Transplant Cytomegalovirus by Madaline Spencer| Published on: Sep 8, 2026 Neil Inhaber, MD, FRCPC, Therapeutic Area Head of Global Medical, Rare Disease at Takeda, discusses data on maribavir in post-transplant cytomegalovirus (CMV) presented at the American Transplant Congress 2026. https://checkrare.com/data-on-maribavir-in-post-transplant-cytomegalovirus/

Vaccine generates durable immune responses in people at high risk for pancreatic cancer Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops. Written byAndrea Corona

Vaccine generates durable immune responses in people at high risk for pancreatic cancer Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops. Written byAndrea Corona https://www.drugdiscoverynews.com/vaccine-generates-durable-immune-responses-in-people-at-high-risk-for-pancreatic-cancer-17365?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--kLSTjOl2-5yLrwYxQvdbgb_wt2C9NFXdHV0LM3qWqQlAxVxL0NgBOB30vvqo9iA1tMuQFrGMcN2vmpyo8FiiRs7hf3w&_hsmi=437947290&utm_content=437947290&utm_source=hs_email Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest five-year survival rates of any cancer, in large part because it is rarely caught early. Most cases are diagnosed at advanced stages, when surgery is no longer an option and systemic treatment options remain limited. For the roughly 10 percent of cases driven by hereditary predisposition, high-risk individuals are currently managed through surveillance — watching and waiting for signs of transformation into cancer with few tools to intervene before that happens.

Reengineering cancer vaccines for durable immune memory Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence. Written byBree Foster, PhD

Reengineering cancer vaccines for durable immune memory Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence. Written byBree Foster, PhD https://www.drugdiscoverynews.com/reengineering-cancer-vaccines-for-durable-immune-memory-17293?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9Wf45ek10ft4XC3MHmJ5JCsUEoGXjXIkY24MxKSrghK_wqgYfLBDF0w4wwQJi4bV0wDrb-E0Nwhnn_55l7FUgGmmirgw&_hsmi=437947290&utm_content=437947290&utm_source=hs_email When most people think of vaccines, they think of prevention — an injection that trains the immune system to produce antibodies against infectious diseases such as measles or polio. However, cancer vaccines are different. Rather than preventing disease, cancer vaccines are a type of immunotherapy designed to stimulate the immune system to attack cancer cells that are already present in the body. However, they have historically struggled to deliver consistent clinical benefit.

Genetic study reveals shared pathways in OCD and tic disorders Whole-exome sequencing identified 36 genes associated with OCD and chronic tic disorders, expanding researchers’ understanding of the biology underlying both conditions. Written byBree Foster, PhD

Genetic study reveals shared pathways in OCD and tic disorders Whole-exome sequencing identified 36 genes associated with OCD and chronic tic disorders, expanding researchers’ understanding of the biology underlying both conditions. Written byBree Foster, PhD https://www.drugdiscoverynews.com/genetic-study-reveals-shared-pathways-in-ocd-and-tic-disorders-17502 For more than two decades, researchers have been collecting DNA from families affected by obsessive-compulsive disorder (OCD) and chronic tic disorders (CTDs). When they began, the technologies needed to make sense of these samples were still developing, and it was unclear whether the effort would reveal any genes with a meaningful role in the disorders.

Personalized vaccines work, making them is the hard part The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight. Written byAndrea Corona

Personalized vaccines work, making them is the hard part The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight. Written byAndrea Corona https://www.drugdiscoverynews.com/personalized-vaccines-work-making-them-is-the-hard-part-17504?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8N5tTOd4-RyubMruW_HJLjGNydPCVWm6VIr6Vx1FptQTGjvK2jICd1TstVjJWpu1x_QQAcb2zlK9Y1Vtx5fwgfHFhWwA&_hsmi=437947290&utm_content=437947290&utm_source=hs_email Personalized mRNA cancer vaccines just cleared their biggest scientific hurdle. Recent Phase 3 data in melanoma showed the approach works in the clinic. But the possible implications of the findings are only as promising as the industry's ability to materialize them.

Decoding the Updated CRC Screening Guidelines Chloe E. Atreya, MD, PhD; Carolina Bernabe, MD; Christopher Lieu, MD, FASCO; Emil Lou, MD, PhD

https://www.medscape.com/viewarticle/decoding-updated-crc-screening-guidelines-2026a1000tsw Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States and the most common in adults younger than 50. Early detection through screening is key to boosting survival, improving quality of life, and reducing the financial burden of treatment costs.

Many New Drugs Were Approved After Just One Study, Analysis Finds (+...)

Many New Drugs Were Approved After Just One Study, Analysis Finds Stanford researchers found that in 2024, more than two-thirds of new drugs approved by the FDA were sanctioned based on findings from a single study, CIDRAP reported. The findings also show a sharp increase in industry-sponsored studies. The senior author of the analysis called the results "concerning, as it allows products to reach the market without independent confirmation of the findings.” https://kffhealthnews.org/morning-briefing/tuesday-september-8-2026/

New Migraine Prevention Guidelines Released Megan Brooks

https://www.medscape.com/viewarticle/new-migraine-prevention-guidelines-released-2026a1000wv9?ecd=WNL_trdalrt_pos1_ous_260908_etid8672170&uac=148436CN&impID=8672170 Updated migraine prevention guidance incorporates calcitonin gene-related peptide (CGRP)-targeted therapies and places greater emphasis on individualized treatment selection based on patient priorities. Developed by the American Academy of Neurology (AAN) and American Headache Society, the updated guideline replaces recommendations issued in 2012 and covers pharmacologic prevention of both episodic and chronic migraine in adults.

Managing Endometrial Cancer: Unpacking the Data Behind the Latest Immunotherapy Advancements Authors: Ana Oaknin, MD, PhD; Domenica Lorusso, MD, PhD

https://www.medscape.org/viewarticle/managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0?page=1&uac=148436CN&src=mkmcmr_driv_cust_mscpedu_260908-OUS-HONC_NOLO-managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0-cta

Cancer Pain Remains a Major Clinical Challenge Nekane Lauzirika

https://www.medscape.com/viewarticle/cancer-pain-remains-major-clinical-challenge-2026a1000x7k?src= “Pain remains a very common issue among cancer patients; its prevalence continues to be very high,” lamented María Luz Cánovas Martínez, head of the pain unit and the Department of Anesthesiology and Resuscitation at the Ourense University Hospital Complex, Ourense, Spain, in statements to El Médico Interactivo, part of the Medscape Professional Network.

MicroRNA Panel May Predict Early Liver Metastasis in PDAC

https://www.medscape.com/viewarticle/microrna-panel-may-predict-early-liver-metastasis-pdac-2026a1000wtq?src= Researchers developed a machine learning model using circulating exosomal microRNAs that identified patients with pancreatic ductal adenocarcinoma (PDAC) at risk for early liver metastasis after surgery. Patients with a high exosomal microRNA panel score had significantly worse overall survival compared with those who had a low score.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer M. Alexander Otto, PA, MMSc

https://www.medscape.com/viewarticle/fda-approves-camizestrant-esr1-mutated-breast-cancer-2026a1000x85?src= The FDA has granted accelerated approval to camizestrant (Etcamah, AstraZeneca), in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, on the basis of an FDA-authorized test.

We Might Have Been Wrong About How the Immune System Ages Sarah Amandalore

https://www.medscape.com/viewarticle/we-might-have-been-wrong-about-how-immune-system-ages-2026a1000x8n?src= A surprising thing might happen to the immune system if you live long enough: rather than steadily declining, it might adapt to help you survive. A new analysis in Cell Reports adds fresh support to this hypothesis, which emerged in 2019 when researchers at Osaka University, Suita, Japan, first showed that “supercentenarians” — those who live to 110 years and beyond — harbor an unusually high number of a rare immune cell.

Support your mental health, one app at a time September 3, 2026 Office of Connected Care

Support your mental health, one app at a time September 3, 2026 Office of Connected Care https://news.va.gov/149188/support-your-mental-health-one-app-time/?utm_medium=email&utm_source=govdelivery

Telehealth therapy helps Veteran find healing with dignity September 1, 2026 Gwen McMillian Communications Specialist, Digital Health Office

Telehealth therapy helps Veteran find healing with dignity September 1, 2026 Gwen McMillian Communications Specialist, Digital Health Office https://news.va.gov/149108/telehealth-therapy-help-veteran-healing-dignity/?utm_medium=email&utm_source=govdelivery

Naloxone saves lives: What Veterans should know August 31, 2026 Jennifer Burden, Ph.D National Mental Health Director, Residential Rehabilitation and Treatment and Acting National Mental Health Director, Substance Use Disorders

Naloxone saves lives: What Veterans should know August 31, 2026 Jennifer Burden, Ph.D National Mental Health Director, Residential Rehabilitation and Treatment and Acting National Mental Health Director, Substance Use Disorders https://news.va.gov/149137/naloxone-saves-lives-what-veterans-should-know/?utm_medium=email&utm_source=govdelivery

Veterans open up about their keys to recovery September 2, 2026 Tamara M. Campbell, MD, PsyD, DFAPA Executive Director, VHA Office of Mental Health

https://news.va.gov/149185/veterans-open-up-about-their-keys-to-recovery/?utm_medium=email&utm_source=govdelivery The path to recovery from addiction, trauma, depression, anxiety, or other mental health challenges is not linear for every Veteran. Learn how other Veterans found a brighter way forward with help from VA.

105-year-old credits ‘the Good Lord’ for her long life

https://www.foxnews.com/lifestyle?lid=p6cb0qpx926p 105-year-old credits ‘the good Lord’ for her long life: ‘Every day is a blessing’ Great-grandmother credits faith, athletics and 'everything in moderation' for her long life By Teresa Mull Fox News Published September 8, 2026 7:00am EDT https://www.foxnews.com/health/105-year-old-credits-good-lord-long-life-every-day-blessing

Dangerous mosquito-borne virus spreads in one state as officials warn of rising cases

https://www.foxnews.com/health Dangerous mosquito-borne virus spreads in one state as officials warn of rising cases Florida mosquito-control agencies are stepping up surveillance, inspections and spraying By Teresa Mull Fox News Published September 7, 2026 1:05pm EDT https://www.foxnews.com/health/dangerous-mosquito-borne-virus-spreads-one-state-officials-warn-rising-cases

Cracking the Code: Optimizing Outcomes in All Patients With High-Risk HR+/HER2-Negative Early Breast Cancer Authors: Manali Bhave, MD; Shaheenah Dawood, MBBCh, MPH, FACP; Erika Hamilton, MD, FASCO

https://www.medscape.org/viewarticle/cracking-code-optimizing-outcomes-all-patients-high-risk-hr-2026a1000crj?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260906-OUS-HONC-cracking-code-optimizing-outcomes-all-patients-high-risk-hr-2026a1000crj-cta

Redefining the Patient Journey: The Promise and Practice in NTRK Fusion–Positive Cancers Authors: Theodore W. Laetsch, MD; Nicole A. Cipriani, MD; Herbert H. Loong, MBBS; Jonathan C. Trent, MD, PhD

https://www.medscape.org/viewarticle/redefining-patient-journey-promise-and-practice-ntrk-fusion-2026a1000lot?page=1&src=mkmcmr_driv_stan_mscpedu_260906-OUS-HONC-redefining-patient-journey-promise-and-practice-ntrk-fusion-2026a1000lot-cta&uac=148436CN

Have you read our ESC Congress 2026 content? (+...)

Catheter ablation for symptomatic atrial fibrillation Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial Rolf Wachter, MDa Send email to rolf.wachter@medizin.uni-leipzig.de ∙ Patrick Haag, MDb ∙ Tobias Uhe, MDa ∙ Miroslav Bacak, PhDc ∙ David Petroff, PhDc ∙ Mathias Forkmann, MDd ∙ et al. (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial Open Access https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01558-8/fulltext?dgcid=hubspot_email_conferencealerts_esc26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_4KbNX9GG0sIBon7IXi5txJPr778uNuxgLTq-Twtu4Czr9JeAnoYcOcXgTsGsD7AzYUgkfSLfToRbMHyl-VKaC6CF_Sw&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study Free with registration until Sept 8th, 2026 Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study Prof Karen Sliwa, MD PhDa,* Send email to karen.sliwa-hahnle@uct.ac.za ∙ Julia Hahnle, MDa,* ∙ Prof Simon Stewart, MDe ∙ Shaazia Allie, MDa ∙ Prof Albertino Damasceno, MD PhDb ∙ Duard Smita,c ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01657-0/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-82o-8ftcrIHVYlBS9gHFTPCjbc2U_3vDgesRNqQ-t9BoPdGPkm3M0cjJqotTVbenGIfxx47hGM_h3SPYBI9y6z-Ysksw&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01426-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-9oMOeWl36jVJnzvOWtfuVgZZKC8W6EZbSEo2JbkXddoIo3l1aKrdMzYelwSrzKGMAxvbmn9mc99soJzZfIXYYfiRA8dQ&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration until Sept 8th, 2026 Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01484-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-9V8CgA4_A6BWwFT2ZwraWbpk2M7_ikrqwrfOhaMtDBTF6HcYJ6QJsPPkkqXOwVFT2QQBSEREvNlIoIWLBLnL8Wh2RLBw&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration until Sept 8th, 2026 Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01654-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-_-fdacbtFc1vXK8MQQipRYGCkXpijnZ9LbZF4OxMubXVTC0qh1d6FfZAbPadXHQY8VGOMnZY7nRW4T27wFOWz_bgHeWw&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration until Sept 8th, 2026 Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01597-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-_nmppg2_wL1OALk-iw_mGm7k5a-O8PdVSaf_nPRhr7JX-qHoiL88oc92dq9NQ43M5o3WJNXzpRY9UOpJKqbjTVH_cG0A&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration until Sept 8th, 2026 Multimodal artificial intelligence-based long-term mortality prediction after transcatheter aortic valve implantation: a multicentre development, validation, and testing study https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00072-5/fulltext?dgcid=hubspot_email_conferencealerts_esc26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_94EOnoD86hYv3UpNC80uHfP2Lr_LjEra5cWZP6s8iENMc8aWcbNSgDKrE6x3NbB7EvNBa6_cdO74c7w2wGFUx368WRg&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Open Access Contributions of diet and lifestyle to sex differences in ischaemic heart disease burden in Central Europe: an analysis of the Global Burden of Disease Study 2023 https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00258-9/fulltext?dgcid=hubspot_email_conferencealerts_esc26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8NH95b3jQhZSwKf-D6fpgmuckkH5U0pIO_7aXu-bqjiTkDSkXIA9A0HFwIF3F9nHTQVsqZeATiXH6ItUULAfTdAVthZw&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Open Access SERIES Cardiovascular disease in pregnancy: physiology, global burden, risk stratification, and opportunities in care https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01234-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-84015CiFfyB68ezI5uJ6ml3EWLIQ7MZwFcDXRKSGU-0BJXm5Q53de3m4DdnbaAhEn91Wl7gWAOk-ndI2jILiQVHBWKHg&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration Adverse pregnancy outcomes and long-term cardiovascular disease risk https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01235-3/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-8fgfBf_yAtWIFI5TMPABKW9CT17mkQqmQKBJihV0j8gIBfZLSTTwSp0marJJYU5JjhNGXacP61vIaOzX70L3drAeRk3A&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration Hypertensive disorders of pregnancy: risk stratification and management https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00190-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc26&_hsenc=p2ANqtz-8USnv_aXLOzwLCkWJacFU1mmxq3qWENnjJ0o0vsx1ojYx3WhI6jayIpe6p3WAYemprVwbzo2EsQfEdqfOzuzTyx-3q7A&_hsmi=437695803&utm_content=437464180&utm_source=hs_email Free with registration

Chronic Eosinophilic Pneumonia in Man With Persistent Cough Wolfgang Paik

https://www.medscape.com/viewarticle/chronic-eosinophilic-pneumonia-man-persistent-cough-2026a1000x2z Chronic eosinophilic pneumonia (CEP) is an uncommon idiopathic respiratory disorder that can mimic common pulmonary conditions, particularly infectious pneumonia. Diagnosis should be considered when respiratory symptoms and pulmonary opacities do not follow the expected course of infection. Careful assessment of clinical history and serial imaging can help identify patterns that warrant further investigation.

BRCA Mutation Carriers Likely to Have Risk-Reducing Surgery Edited by Katie Lennon September 07, 2026

https://www.medscape.com/viewarticle/brca-mutation-carriers-likely-have-risk-reducing-surgery-2026a1000x44?src= Women with pathogenic variants (PVs) in BRCA1/2 genes were more than seven times as likely to undergo risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) as were those carrying genetic variants for which there is “insufficient evidence” for discussion, consideration, or recommendation related to use of either procedure for such patients. Pancreatic screening via endoscopic ultrasound (EUS) or magnetic resonance cholangiopancreatography (MRCP) was used by fewer than 11% of eligible women, regardless of gene type, within 12 months after genetic testing.

NICE Expands Drug Access for Young Children With NF1 Tumours Edited by Zeel Mehta

https://www.medscape.com/viewarticle/nice-expands-drug-access-young-children-nf1-tumours-2026a1000x4h?src= The National Institute for Health and Care Excellence (NICE) has recommended mirdametinib (Ezmekly, Merck Serono) as an option for children and young people aged 2-17 years with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1). Around 200 patients are expected to benefit.

Bilateral Mastectomy Rises in Young BRCA1/2 Carriers Edited by Victoria Stern September 07, 2026

https://www.medscape.com/viewarticle/bilateral-mastectomy-rises-young-brca1-2-carriers-2026a1000wsl?src= Among young women carrying germline BRCA1/2 pathogenic or likely pathogenic variants diagnosed with early-onset breast cancer, bilateral mastectomy rates increased substantially over two decades, rising from 8% in 2000 to 44.4% in 2020, a recent international study found. Women who underwent genetic testing before or at the time of diagnosis were significantly more likely to undergo bilateral mastectomy compared with those tested after diagnosis.

Sunscreen, Collagen: Do Viral Social Media Claims Hold Up? Elisa Riera

https://www.medscape.com/viewarticle/sunscreen-collagen-do-viral-social-media-claims-hold-2026a1000x57?src= In recent months, a new way of applying sunscreen has circulated on social media: applying it only to selected areas of the face, such as the forehead, nose, and cheekbones, while leaving other areas exposed to the sun. The stated aim is to create a contouring effect through selective tanning, a practice known as “tanning contouring.” This trend has emerged with a broader wave of content questioning the need for sun protection or warnings about alleged health risks.

Mismatch Repair Deficiency Linked to Improved Survival in Resectable Oesophagogastric Cancer

https://www.medscape.com/viewarticle/mismatch-repair-deficiency-linked-improved-survival-2026a1000wp8?src= In an analysis of patients with resectable oesophagogastric adenocarcinoma from two large trials, those with mismatch repair-deficient (MMRd) tumours treated with perioperative chemotherapy had significantly better survival than those with MMR-proficient (MMRp) tumours, and chemotherapy did not erase that advantage.

EMA Probes Injectable Iron Medicines for Bone Risks Edited by Zeel Mehta

https://www.medscape.com/viewarticle/ema-probes-injectable-iron-medicines-bone-risks-2026a1000x5x?src= Reports of severe hypophosphatemia linked to injectable iron medicines — including cases of osteomalacia after just one or two doses and in patients with no recognized risk factors — have prompted a European safety review. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has launched the review across all injectable iron formulations, not only ferric carboxymaltose, amid concerns that current risk-minimization measures may not be sufficient.

Next Generation Imaging (videos)

Next Generation Imaging Radiology is a cornerstone of modern healthcare, significantly improving patient care through accurate diagnostics, effective treatment planning, and ongoing patient monitoring. As innovations in imaging reshape patient care, it is essential for radiologists, radiologic technologists, specialists, and referring clinicians to stay informed about the latest best practices in radiology. This curated resource offers CME activities that feature insights from leading experts, along with engaging slide kits, clinical articles, and links to valuable imaging resources. Together, these materials create a dynamic community of learning focused on enhancing patient care and achieving positive outcomes. https://www.medscape.org/advances/advancing-clinical-excellence-precision-imaging-2025a1000ayx

Elevating CLL Care: Integrating Evidence, Guidelines, and the Patient Perspective Authors: Jennifer A. Woyach, MD; Stephan Stilgenbauer, MD; Lorna Warwick

https://www.medscape.org/viewarticle/elevating-cll-care-integrating-evidence-guidelines-and-2026a1000nxr?page=1&src=mkmcmr_driv_stan_mscpedu_260907-OUS-HONC-elevating-cll-care-integrating-evidence-guidelines-and-2026a1000nxr-cta&uac=148436CN

Rare Endocrine Exchange: Why This Conversation Matters by CheckRare Staff| Published on: Aug 18, 2026

Rare Endocrine Exchange Episode 1: Why Rare Endocrine Matters Rare endocrine disorders can be difficult to recognize, challenging to diagnose, and even harder for patients to navigate. For many patients, the journey to an accurate diagnosis can take years. Rare Endocrine Exchange, a new podcast from CheckRare, aims to change that. https://checkrare.com/rare-endocrine-exchange-why-this-conversation-matters/

Beyond AChR: Recognizing and Treating MuSK Ab+, LRP4, Ab+ and Triple Seronegative Myasthenia Gravis

New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer

The CheckRare Brief (audio) 5 videos https://www.youtube.com/watch?v=8L_3Jc-LcUM&list=PLM1cjjMgXvps

Father Pursues Gene Therapy for Sons With Rare Genetic Variations of Duchenne Muscular Dystrophy

Decoding Delays, Connecting the Care: The Challenge of Diagnosing Rare Endocrine Disorders

New Graves’ Disease Community Website by Madaline Spencer| Published on: Sep 7, 2026

New Graves’ Disease Community Website by Madaline Spencer| Published on: Sep 7, 2026 Christine Gustafson, Executive Director and CEO of the TED Community Organization, discusses the new Graves’ Community website. https://checkrare.com/new-graves-disease-community-website/

The CheckRare Brief Podcast +++ New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | The CheckRare Brief Ep 5 by CheckRare Staff| Published on: Sep 3, 2026

The CheckRare Brief Podcast New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | Ep 5 New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | The CheckRare Brief Ep 5 by CheckRare Staff| Published on: Sep 3, 2026 In this episode of The CheckRare Brief, we discuss four recent FDA approvals, including LISRAYA for dermatomyositis and Imaavy for warm autoimmune hemolytic anemia (wAIHA), Mimrylo for polycythemia vera (PV), and Rasonque for pancreatic cancer. https://checkrare.com/new-fda-approvals-for-rare-diseases-from-autoimmune-disorders-to-pancreatic-cancer-the-checkrare-brief-ep-5/ Getting a Rare Disease Drug Approved Is Only Half the Battle | Ep 4 Two new rare disease approvals, ongoing drug supply problems affecting patients, and a major acquisition that illustrates how rare disease therapies move from small biotech companies into the hands of larger pharmaceutical companies. https://checkrare.com/getting-a-rare-disease-drug-approved-is-only-half-the-battle-the-checkrare-brief-ep-4/ FDA Approves Multiple Myeloma Treatment, Denies Neuroendocrine Tumors Treatment | Ep 3 FDA’s approval of Zenbexus (iberdomide) to treat patients with multiple myeloma, the complete response letter issued to ITM-11 to treat patients with neuroendocrine tumors, and safety concerns about VYKAT XR for Prader-Willi syndrome (PWS). https://checkrare.com/fda-approves-multiple-myeloma-treatment-denies-neuroendocrine-tumors-treatment/

Register for the EL-PFDD Meeting September 11th | 9:30 AM – 3:00 PM ET

https://lipodystrophyunited.org/register-el-pfdd-meeting/ Register for Lipodystrophy United's Externally-Led Patient-Focused Drug Development Meeting This meeting is your chance to help decision-makers understand what living with lipodystrophy is really like. Audience participation is a major part of the day. Patients and caregivers in the room will have opportunities to share comments, respond to questions, and add their experiences to the conversation.

Stem Cells

Overview: Stem cell research in space offers great potential to expand our understanding of cellular behavior and therapeutic applications. The International Space Station (ISS International Space Station ) National Laboratory empowers scientists to unravel the mysteries of how microgravity The condition of perceived weightlessness created when an object is in free fall, for example when an object is in orbital motion. Microgravity alters many observable phenomena within the physical and life sciences, allowing scientists to study things in ways not possible on Earth. The International Space Station provides access to a persistent microgravity environment. influences stem cell proliferation, differentiation, and function. These investigations are unlocking key mechanisms that could significantly enhance stem cell performance, paving the way for accelerated advancements in regenerative medicine and biotechnology. https://issnationallab.org/research-and-science/space-research-overview/research-areas/in-space-production-applications/stem-cells/

In-Space Production: Tissue Engineering and Regenerative Medicine

In-Space Production: Tissue Engineering and Regenerative Medicine The field of tissue engineering and regenerative medicine spans from cell-based studies to organoid growth and 3D printing of human tissues. Regenerative medicine research is aimed at improving health and longevity, using tissue chips and a biofabrication facility (Abbreviation: BFF) The BFF is a 3D bioprinter on the ISS capable of printing human tissue from bioinks mixed with living cells. This ISS National Lab commercial facility is owned and operated by Redwire Space. to address larger challenges with real-world applications. Tissue engineering has many applications but often includes culturing tissues resembling those in the body to model and study human disease, allow higher-accuracy and personalized drug testing, or advance research in organ growth to address the shortage of organs for transplantation. https://issnationallab.org/research-and-science/space-research-overview/research-areas/in-space-production-applications/tissue-engineering-and-regenerative-medicine/

Upward Downloads browse and download past issues of Upward to learn more! +...

https://issnationallab.org/news-and-events/upward-downloads/ The International Space Station (ISS) is a powerful platform in low Earth orbit (LEO) that enables research and development (R&D) not possible on Earth. With its persistent microgravity, access to the extreme space environment, and unique vantage point, this one-of-a-kind orbiting laboratory allows investigators to advance R&D in a wide variety of disciplines.

Case Studies +...

Case Studies Researchers from academic institutions, commercial companies, nonprofit organizations, and government agencies are leveraging the unique environment of space to gain valuable insights. Each case study below showcases an ISS National Laboratory project or initiative. Learn from those who have already benefited from the station’s unique capabilities. https://issnationallab.org/case_studies/

Microgravity improves production of artificial retina to restore vision ISS NATIONAL LAB OPPORTUNITY

Microgravity improves production of artificial retina to restore vision ISS NATIONAL LAB OPPORTUNITY In space, the reduction in gravity-driven forces enables the production of artificial retinas with much more uniform protein layers, improving quality and reducing waste. https://issnationallab.org/case_study/advancing-artificial-retinas/ LambdaVision developed an artificial retina to restore vision in patients with blindness from macular degeneration. The company creates thin films made of hundreds of layers of a light-sensitive protein, and small, oval-shaped artificial retinas are punched out of the film. During manufacturing on Earth, sedimentation and buoyancy-driven convection cause inconsistencies in the layers, which can render parts of the film unusable. In space, these gravity-driven forces are greatly reduced, making it the ideal environment for manufacturing the films. LambdaVision has conducted nine ISS International Space Station investigations to advance an automated production system, developed in collaboration with ISS National Lab Commercial Service Provider Implementation Partners that own and operate commercial facilities for the support of research on the ISS or are developing future facilities. Space Tango, to produce artificial retinas in space.

Scientists identify new drug target to combat airborne tuberculosis

https://www.news-medical.net/news/20260826/Scientists-identify-new-drug-target-to-combat-airborne-tuberculosis.aspx?utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=drug_discovery_newsletter_3_september_2026 Tuberculosis bacteria released into the air from infected individuals dry out to form infectious particles that are second only to measles in contagiousness. Weill Cornell Medicine investigators have discovered specific mechanisms that enable the bacteria not only to survive drying but also to generate mutations linked to antibiotic resistance. This suggests that transmission involves more than the passive movement of bacteria between people and may be a period during which the pathogen evolves.

Advancing degrader and proximity-based drug development

https://www.news-medical.net/industry-focus/Advancing-degrader-and-proximity-based-drug-development?utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=drug_discovery_newsletter_3_september_2026 A decade of development has yielded the targeted protein degradation (TPD) field its first drug approval with Arvinas' Veppanu. Alongside the 2026 market resurgence, this clinical achievement is poised to inspire novel strategies and elevate TPD to a major milestone. Targeted protein degradation is reshaping drug discovery, from PROTACs to molecular glues and proximity-based approaches. This eBook explores the scientific, technical, and development considerations helping teams identify stronger candidates, improve selectivity, and accelerate therapeutic innovation across complex disease areas where conventional modalities may fall short for patients worldwide today.

Not All Reporters Reveal the Same Biology

Choosing a Reporter Assay that Fits Your Research The right luciferase reporter can transform your research. Finding an assay that matches your experimental needs requires clarity on what matters most: sensitivity, throughput, signal duration. This guide will help you choose the right luciferase reporter system for your experimental goals. Not All Reporters Reveal the Same Biology https://worldwide.promega.com/resources/guides/cell-biology/choosing-a-luciferase-reporter-assay/?utm_source=azonetworks_drugdisc&utm_campaign=global-brand_rt Are you evaluating reporter assays? We put together a guide that walks you through key decision points: signal stability, normalization, throughput requirements and what to consider when your target is at the edge of detection. Find the right assays for your experiments.

Maximizing the impact of your scientific poster: TIPS, TRAPS and TOOLS DATE: 9 September TIME: 12:30–13:30 BST

https://www.news-medical.net/webinar/Maximizing-the-impact-of-your-scientific-poster-TIPS-TRAPS-AND-TOOLS?referrer=AZoNLH1&utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=drug_discovery_newsletter_3_september_2026 [Free Webinar] Maximizing the impact of your scientific poster: TIPS, TRAPS and TOOL Whether you're presenting your first or fiftieth poster, creating a clear, engaging poster and making the most of your session are skills that can significantly increase the impact of your research. Chaired by ELRIG ECP Work Group member Jasmine Trigg, the session offers best practice and practical advice for researchers at every career stage. It will also explore how platforms such as AZoNetwork's Digital Poster Hub can help researchers share their work with a global audience, increasing the visibility and longevity of their research beyond the conference.

Buried underpants and a new definition of kissing win 2026 Ig Nobel prizes The awards highlight weird, funny and improbable research that also makes you think. By Chris Simms

https://www.nature.com/articles/d41586-026-02650-x?utm_source=Live+Audience&utm_campaign=4dd3d42714-nature-briefing-daily-20260904&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Ig Nobels make you laugh, then think The tongue-in-cheek celebration of science known as the Ig Nobel prizes took place last night in Switzerland — the first time in its 36-year history that it was held outside the United States, which the organizers say “has become unsafe for our guests to visit”. The winners included an economics prize for research showing that wealthier individuals take more from a bowl of sweets meant for children than did less-wealthy people; a physics prize for a splash-proof urinal; and a peace prize for evidence that people value friends who are mean to those that they dislike. A breath of fresh air (and a deluge of aeroplanes) Last night, the Ig Nobel prize ceremony lived up to its promise to “first make people laugh, and then make them think”. I’ve watched past events online, but it was another thing entirely to experience traditions such as ‘the paper aeroplane deluge’ in person. I wasn’t sure about my choice of a front-row seat when I realized that many of those planes were heading for the back of my head, but it paid off when I caught one of the pairs of autographed cotton underpants thrown into the audience by the winners of this year’s Ig Nobel in soil science, who buried hundreds of similar pants to investigate soil health. The prizes are handed out by winners of the other Nobel prize (the Swedish one), who also receive gifts in turn. This year, these included glasses of milk from the team that discovered the proteins in cockroach milk contain three times as much energy as those in cow’s milk. The Nobel laureates also got a pair of the aforementioned underpants — and the sight of Swiss astrophysicist Michel Mayor, on his home turf, gamely wearing them on his head made the trip even more worthwhile. The Ig Nobels capture a type of irreverent, sometimes surreal humour that pervades many laboratories and research groups, powered by the love of science, a desire to puncture some of its pompousness, and too much coffee. It’s the same urge that prompted groups to show up to the Ig Nobel event en masse and in costume, or inspired the milk researchers to wear matching ‘cockroach is my spirit animal’ T-shirts. Or indeed, that inspired the discoverer of the first exoplanet orbiting a Sun-like star to put a pair of underpants on his head, just for laughs. After the last paper aeroplane was flown and the final, fungi-themed opera was sung, many post-event conversations turned to the difficulties facing scientists around the world. The consensus was that in hard times, a sense of humour is a survival skill. I certainly felt recharged by this unabashedly nerdy celebration of what makes science so much fun: finding things out. It’s a feeling that will be keeping me going until next year. See you in Antwerp!

Could mending damaged DNA prolong life? Inspired by long-lived animals — and human centenarians — researchers are hunting for ways to enhance DNA repair and extend healthspan. By Elizabeth Quill

https://www.nature.com/articles/d41586-026-02385-9?utm_source=Live+Audience&utm_campaign=4dd3d42714-nature-briefing-daily-20260904&utm_medium=email&utm_term=0_-33f35e09ea-50432164 DNA damage seems to underlie many of the hallmarks of ageing, including chronic inflammation, metabolic malfunctions and protein-folding problems. But our bodies already have a wonderfully efficient DNA-repair system that heals countless wounds to this molecule — from ultraviolet light, for example — every day. Scientists are asking: if DNA damage is at the root of ageing, can boosting DNA repair slow the process, keeping people healthy for longer? Research into relatively long-lived species, such as bowhead whales (Balaena mysticetus) and naked mole rats (Heterocephalus glaber), and into the genetics of human centenarians, is sparking fresh optimism about the approach.

Landmark pancreatic cancer drug shows potential against lung cancer too Results bolster hopes that the drug daraxonrasib could prove effective against a variety of tumours. By Heidi Ledford

https://www.nature.com/articles/d41586-026-02745-5?utm_source=Live+Audience&utm_campaign=4dd3d42714-nature-briefing-daily-20260904&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Results from a small clinical trial show that the drug daraxonrasib (Rasonque) could be an effective treatment for lung cancer. The findings come just one week after the US Food and Drug Administration (FDA) approved the medicine for the treatment of advanced pancreatic cancer. A larger study in which people with lung cancer are randomly assigned to receive daraxonrasib or standard chemotherapy is now under way, the results of which could inform the FDA’s decision to approve the drug as a lung cancer treatment.

Immune therapy engineered inside the body eases multiple sclerosis Results from a small trial suggest a modified virus can instruct the immune system to wipe out disease-causing cells. By Rachel Fieldhouse

https://www.nature.com/articles/d41586-026-02765-1?utm_source=Live+Audience&utm_campaign=4dd3d42714-nature-briefing-daily-20260904&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Sixteen people with autoimmune conditions have had their symptoms relieved by a treatment that produces disease-fighting immune cells inside their bodies. Researchers used a modified virus to deliver the genetic instructions for making chimeric antigen receptors (CARs) on participants’ T cells. These CAR T cells target antibodies produced by other immune cells, which attack the body’s own healthy tissue in autoimmune diseases. The findings are a proof of concept for in vivo CAR-T-cell therapy, says clinician-researcher David Simon, which is cheaper and faster to produce than is lab-made CAR-T.

Magic-mushroom compound blocks a severe side effect of chemotherapy in mice Study shows that psilocybin acts on nerves to prevent the painful condition called peripheral neuropathy. By Max Kozlov

https://www.nature.com/articles/d41586-026-02744-6?utm_source=Live+Audience&utm_campaign=4dd3d42714-nature-briefing-daily-20260904&utm_medium=email&utm_term=0_-33f35e09ea-50432164 The psychoactive compound psilocybin seems to protect mice from a debilitating side-effect of chemotherapy called neuropathy. As many as 60% of people treated with platinum-based chemotherapy drugs can experience neuropathy, which causes a constant feeling of burning, or pins and needles, in their hands and feet. Just two doses of psilocybin administered before chemo completely prevented the adverse effect in mice, which could argue for expanding the use of psychedelic compounds beyond the conventional uses in mental-health conditions such as depression, says oncologist and study co-author Moran Amit.

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&src=mkmcmr_driv_stan_mscpedu_260906-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta&uac=148436CN

Inherited genes could help make CAR T therapies safer and more effective Written byBree Foster, PhD ++

Inherited genes could help make CAR T therapies safer and more effective Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design. Written byBree Foster, PhD https://www.drugdiscoverynews.com/inherited-genes-could-help-make-car-t-therapies-safer-and-more-effective-17405?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9YU5unYeLBgxEsUPlpiNpXsaYjiaJnbg65mdyQWwhUrct0zRIai-4g_WhQIJida0b-qzqMqz007lzQ2pNw8yxhcJl9ug&_hsmi=437396178&utm_content=437396178&utm_source=hs_email Since the first CAR T therapy won approval in 2017, these engineered immune cells have transformed treatment for several blood cancers. However, despite promising responses in many patients, CAR T remains unpredictable. Some patients experience severe cytokine release syndrome (CRS) or neurotoxicity, while others tolerate treatment well. Likewise, the extent to which CAR T cells expand after infusion, a key driver of therapeutic success, varies widely between individuals. A new design framework for mRNA vaccines could improve efficacy and safety New findings suggest that the location of mRNA expression in the body plays a critical role in shaping T cell responses, opening the door to more precise and effective mRNA-based treatments. Written byBree Foster, PhD https://www.drugdiscoverynews.com/a-new-design-framework-for-mrna-vaccines-could-improve-efficacy-and-safety-17156?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_47JLaZ0V8Sn7Gp2MlR-ezWU39k7K1NbH0Xa4r1Ix__AtIywMUjbft9HAPeTQl_x8-PK02jJ45tIvARuNCsY6dEXSRHg&_hsmi=437396178&utm_content=437396178&utm_source=hs_email A new study from the Icahn School of Medicine at Mount Sinai challenges a central assumption in mRNA vaccine biology, showing that immune cells are not the only — or even the primary — determinant of vaccine effectiveness. Instead, non-immune cells such as muscle and liver cells play a previously underappreciated role in shaping immune responses, with major implications for mRNA vaccines and therapeutics.

Novartis pauses autoimmune CAR T trials following three deaths The first gene therapy for Huntington's disease submitted to the FDA, an mRNA flu vaccine advances to Phase 3 trials, an antibody drug for celiac disease, and more led the news this week. Brought to you byDDN editorial team

Novartis pauses autoimmune CAR T trials following three deaths The first gene therapy for Huntington's disease submitted to the FDA, an mRNA flu vaccine advances to Phase 3 trials, an antibody drug for celiac disease, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/novartis-pauses-autoimmune-car-t-trials-following-three-deaths-17501 Novartis has hit the brakes across eight early- and mid-stage trials of its experimental CD19-directed CAR T therapy rapcabtagene autoleucel (rap-cel). The company made the move after three patients died from immune effector cell-associated hemophagocytic syndrome (IEC-HS), a rare but potentially fatal hyperinflammatory complication of CAR T treatment. The pause affects the therapy’s immunology and neuroscience programs, including Phase 2 AUTOGRAPH studies in systemic lupus erythematosus, lupus nephritis, systemic sclerosis, ANCA-associated vasculitis, and idiopathic inflammatory myopathies, as well as Phase 1/2 trials in rheumatoid arthritis, Sjögren’s disease, myasthenia gravis, and multiple sclerosis. Novartis’ oncology studies of rap-cel remain ongoing. The move comes as drugmakers increasingly explore CAR T beyond cancer, raising new questions about how the therapy’s potentially serious toxicities can be managed in autoimmune diseases. Bristol Myers Squibb has also paused enrollment in its autoimmune studies of zolacabtagene autoleucel (zola-cel) after observing transient, reversible inflammatory events, although the company is still conducting the trials. – Bree Foster

Novartis pauses immunology, neuro CAR-T studies after three patient deaths Elizabeth S. Eaton Published : September 01, 2026

https://firstwordpharma.com/story/7935226 Novartis has temporarily paused screening, randomisation and dosing in eight early- and mid-stage studies of its CD19-directed CAR-T cell therapy rapcabtagene autoleucel (rap-cel) after three fatal cases of immune effector cell-associated haemophagocytic syndrome (IEC-HS), a company spokesperson confirmed to FirstWord on Monday. The pause only affects immunology and neuroscience trials of the experimental cell therapy, leaving the oncology programme ongoing.

Managing Myeloproliferative Neoplasms: Practice Your Skills in These Virtual Patient Simulations Authors: Claire N. Harrison, DM, FRCP, FRCPath; Haifa Kathrin Al-Ali, MD

https://www.medscape.org/viewarticle/managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o?page=1&src=mkmcmr_driv_psims_mscpedu_260905-OUS-HONC-managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o-cta&uac=148436CN

Lessons From the Real World: Treating High Risk HR+/HER2- Breast Cancer According to the Latest Evidence Authors: Nadia Harbeck, MD, PhD; Stephen Johnston, MA, FRCP, PhD; Sara Tolaney, MD, PhD

https://www.medscape.org/viewarticle/lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260905-OUS-HONC-lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd-cta

Collaborative Excellence in Cancer Care: A Multidisciplinary Approach to Integrating Subcutaneous Immunotherapy Authors: Solange Peters, MD, PhD; Mauricio Burotto, MD; Jürgen E. Gschwend, MD, PhD

https://www.medscape.org/viewarticle/collaborative-excellence-cancer-care-multidisciplinary-2026a1000knq?page=1&src=mkmcmr_driv_stan_mscpedu_260906-OUS-HONC-collaborative-excellence-cancer-care-multidisciplinary-2026a1000knq-cta&uac=148436CN

Before McDonald's and Starbucks, Americans packed these once-beloved lunch counters

https://www.foxnews.com/lifestyle?lid=cdlvu2rzq0sx Before McDonald's and Starbucks, Americans packed these once-beloved lunch counters From Woolworth's lunch counters to soda fountains, casual eateries reshaped public life before fast food took over By Teresa Mull Fox News Published September 5, 2026 8:00am EDT https://www.foxnews.com/food-drink/before-mcdonalds-starbucks-americans-packed-once-beloved-lunch-counters

Scientists discover new tick-borne virus after testing thousands of patients with mysterious illnesses

https://www.foxnews.com/health Scientists discover new tick-borne virus after testing thousands of patients with mysterious illnesses Asian longhorned tick nairovirus was found in 10.4% of more than 3,000 patients bitten by ticks Melissa Rudy By Melissa Rudy Fox News Published September 4, 2026 2:42pm EDT https://www.foxnews.com/health/scientists-discover-new-tick-borne-virus-testing-thousands-patients-mysterious-illnesses

A Body at War: New Immune Reset By Ivanhoe Broadcast News on August 13, 2026

A Body at War: New Immune Reset By Ivanhoe Broadcast News on August 13, 2026 DENVER, Colo. (Ivanhoe Newswire) — More than 50 million Americans live with autoimmune diseases — conditions in which the immune system mistakenly attacks the body it’s supposed to protect. For many, treatment can mean years of medications to quiet that attack. But now, doctors are testing something far more aggressive: ways to reset or even replace the immune system itself. https://www.ivanhoe.com/family-health/a-body-at-war-new-immune-reset/

I’m Fine! The Men Who Don’t Look Depressed By Ivanhoe Broadcast News on September 1, 2026

I’m Fine! The Men Who Don’t Look Depressed By Ivanhoe Broadcast News on September 1, 2026 ORLANDO, Fla. (Ivanhoe Newswire) — September is Suicide Prevention Month. And while more than 21 million American adults experience a major depressive episode each year, experts say depression in men is often missed because it doesn’t always look the way people expect. Ivanhoe explains why recognizing often overlooked signs could save a life. https://www.ivanhoe.com/family-health/im-fine-the-men-who-dont-look-depressed/

The Memory Trap: Lost In The Camera Roll By Ivanhoe Broadcast News on September 11, 2026

The Memory Trap: Lost In The Camera Roll By Ivanhoe Broadcast News on September 11, 2026 Orlando, Fla. (Ivanhoe Newswire) — We’re living through the most photographed time in history. We’re taking more photos than ever before, about 20 every day. That’s more than seven thousand photos a year, but neuroscientists say our brains aren’t built to record everything. They remember what we pay attention to, and when our attention shifts to getting the perfect photo we may encode fewer details of the experience itself. https://www.ivanhoe.com/?p=37573&preview=1&_ppp=a009820674

Planning A Career In The Age Of AI By Ivanhoe Broadcast News on September 10, 2026

Planning A Career In The Age Of AI By Ivanhoe Broadcast News on September 10, 2026 Orlando, Fla. (Ivanhoe Newswire) — College has always been about preparing for the future. But today’s students are facing a question their parents never had to ask, will AI replace the job I’m studying for? About 70 percent of college students say they worry artificial intelligence could hurt their career prospects. And some are even changing their majors because of it. https://www.ivanhoe.com/?p=37570&preview=1&_ppp=bb1b16fa93

What Your “Gut Feeling” Is Telling You About Your Health By Ivanhoe Broadcast News on September 9, 2026

What Your “Gut Feeling” Is Telling You About Your Health By Ivanhoe Broadcast News on September 9, 2026 ORLANDO, Fla. (Ivanhoe Newswire) — Your gut microbiome is made of trillions of microbes such as bacteria, viruses, yeast, and fungi. In the past 10 to 15 years researchers have made big breakthroughs on how much your gut microbiome affects your overall health. Ivanhoe explains how keeping these colon-dwelling tenants happy can keep you healthy. https://www.ivanhoe.com/?p=37567&preview=1&_ppp=b7479382b5

Gum Disease Beyond Your Mouth By Ivanhoe Broadcast News on September 8, 2026

Gum Disease Beyond Your Mouth By Ivanhoe Broadcast News on September 8, 2026 ORLANDO, Fla. (Ivanhoe Newswire) — Gum disease is a very common condition, with nearly half the adults in the U.S. age 30 and older having some form of gum disease. That jumps to 70 percent for people 65 years and older. If left untreated, gum disease can lead to some very serious complications that go beyond your mouth. https://www.ivanhoe.com/?p=37564&preview=1&_ppp=e3b0b62a33

Breath Of Hope: ECMO Gives Mom a Second Chance By Ivanhoe Broadcast News on September 7, 2026

Breath Of Hope: ECMO Gives Mom a Second Chance By Ivanhoe Broadcast News on September 7, 2026 RALEIGH, NC. (Ivanhoe Newswire) — As we head into fall, we also head into cold and respiratory virus season. While most people recover without serious problems, some viral infections can lead to life-threatening pneumonia that requires the most advanced life support available. That’s what happened to a 41-year-old mom who thought she was just fighting a stubborn cold. https://www.ivanhoe.com/?p=37561&preview=1&_ppp=84af4fa098

Clinical Turning Points Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT

https://na.eventscloud.com/website/98569/ Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Join us for this interactive 90-minute CME/CE symposium featuring livestreaming and social media simulcast. Expert faculty will examine critical clinical turning points to overcome inertia and uncertainty, optimizing treatment decisions—particularly when considering escalation to disease-directed therapy. Walk away with practical strategies to evaluate disease control, integrate emerging clinical evidence, and optimize management across the SM continuum.

Acknowledging the Rare Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT

https://na.eventscloud.com/website/98255/ This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia.

The APP Role in Advancing Anti-HER2 Treatment for Gastroesophageal Adenocarcinoma CME/CNE/CPE/IPCE Minneapolis Convention Center Thursday, October 15, 2026 9:30 am - 10:30 am CT

https://na.eventscloud.com/website/98965/ Novel anti-HER2 regimens with unique safety profiles are poised to expand treatment options for patients with gastroesophageal adenocarcinoma (GEA). Designed specifically for advanced practice professionals, this 60-minute live symposium explores where new agents fit into care for human epidermal growth factor receptor 2 (HER2)-positive GEA and best approaches for toxicity management.

Free Virtual Breast Cancer Conference SEPTEMBER 18-19, 2026

https://events.medscapelive.org/ereg/newreg.php?eventid=853062&categoryid=5844745&discountcode=VIP26

Study uncovers cause of abnormal breathing in Rett syndrome

https://www.news-medical.net/news/20260901/Study-uncovers-cause-of-abnormal-breathing-in-Rett-syndrome.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=parkinson_s_disease_newsletter_2_september_2026 Hyperventilating. Breath holding until they turn blue. This abnormal breathing is frequent and disturbing in people with Rett syndrome, a rare genetic disease. Now University of Connecticut researchers report in the Sept. 1 issue of Current Biology why those episodes happen, and show how medications for an entirely different disease might help.